Cost-effectiveness of Pemigatinib As a Second-Line Treatment for Advanced Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions in Taiwan: from the Evidence of the Phase II Trial and the Perspective of Taiwan's National Health Insurance Administration.
COST EFFECTIVENESS AND RESOURCE ALLOCATION（2023）
关键词
Pemigatinib,Intrahepataic cholangiocarcinoma,Targeted therapy,Economic evaluation,Cost-effectiveness analysis,Price listing strategy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要